1. Apelin is an angiogenesis stimulating peptide found in hearts. Deficiency in the peptide apelin is associated with heart failure, pulmonary hypertension and diabetes. synthetic peptide that targets pathways in the heart and promotes blood vessel growth could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.
2.
polypill combines three blood pressure lowering medicines (ramipril, thiazide and atenolol) with a lipid-lowering drug (simvastatin) and aspirin to thin the blood.
3.New biomarker for diagnosis, prognosis and treatment of heart disease: “catalytic iron” or “free iron” as a potential biomarker in forecasting the causes of cardiovascular disease.“The new biomarker will help in three ways. Firstly, the marker is able to detect acute coronary syndrome (heart attack) within three hours of the onset of chest pain. This will enable the cardiologist to institute treatment early. Early treatment has been shown to improve outcomes. Secondly, the marker will be able to separate patients at higher risk for death and adverse cardiac events right at the time of admission. Thirdly, the marker is capable of detecting cardiovascular disease in general population. This will help epidemiologists to study the burden of heart disease in population.”
4.Research explains how gut microbes can inactivate cardiac drugs
microbes in the human gut can influence how certain drugs work in the body .
2.
polypill combines three blood pressure lowering medicines (ramipril, thiazide and atenolol) with a lipid-lowering drug (simvastatin) and aspirin to thin the blood.3.New biomarker for diagnosis, prognosis and treatment of heart disease: “catalytic iron” or “free iron” as a potential biomarker in forecasting the causes of cardiovascular disease.“The new biomarker will help in three ways. Firstly, the marker is able to detect acute coronary syndrome (heart attack) within three hours of the onset of chest pain. This will enable the cardiologist to institute treatment early. Early treatment has been shown to improve outcomes. Secondly, the marker will be able to separate patients at higher risk for death and adverse cardiac events right at the time of admission. Thirdly, the marker is capable of detecting cardiovascular disease in general population. This will help epidemiologists to study the burden of heart disease in population.”
4.Research explains how gut microbes can inactivate cardiac drugs
microbes in the human gut can influence how certain drugs work in the body .
Comments
Post a Comment